A case of sialadenitis observed as an irAE of atezolizumab: A case report

Various symptoms emerge as immune-related adverse events of immune checkpoint inhibitor (ICI). A 73-year-old woman, a non-smoker, receiving chemotherapy including atezolizumab for lung adenocarcinoma, presented with fever, bilateral parotid swelling and sicca syndrome after four courses of chemother...

Full description

Saved in:
Bibliographic Details
Published inRespiratory medicine case reports Vol. 50; p. 102068
Main Authors Kumagai, Kosumi, Baba, Tomohisa, Fukushima, Takashi, Tabata, Erina, Nakazawa, Atsuhito, Hagiwara, Eri, Iwasawa, Tae, Ogura, Takashi
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.01.2024
Elsevier
Subjects
Atezolizumab
Case Report
Immune checkpoint inhibitor
Immune-related adverse events
Sialadenitis
Sialadenitis
Immune-related adverse events
Immune checkpoint inhibitor
Atezolizumab
Online AccessGet full text

Cover

More Information
Summary:Various symptoms emerge as immune-related adverse events of immune checkpoint inhibitor (ICI). A 73-year-old woman, a non-smoker, receiving chemotherapy including atezolizumab for lung adenocarcinoma, presented with fever, bilateral parotid swelling and sicca syndrome after four courses of chemotherapy. Because the lesions were not localized, the diagnosis was ICI-related sialadenitis rather than infectious. Prednisolone improved salivary gland swelling quickly. Six months after the last administration of ICI, there was no obvious progression of lung cancer. To our knowledge, this is the first case of sialadenitis caused by atezolizumab. ICI-related sialadenitis may be a good prognostic marker for lung cancer.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:2213-0071
2213-0071
DOI:10.1016/j.rmcr.2024.102068